Los Angeles Capital Management LLC Buys New Shares in NeoGenomics, Inc. (NASDAQ:NEO)

Los Angeles Capital Management LLC purchased a new position in NeoGenomics, Inc. (NASDAQ:NEO) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 74,633 shares of the medical research company’s stock, valued at approximately $1,101,000.

Several other institutional investors have also added to or reduced their stakes in NEO. Edgestream Partners L.P. bought a new stake in shares of NeoGenomics in the 1st quarter valued at about $1,894,000. Bellevue Group AG bought a new stake in NeoGenomics in the first quarter valued at approximately $14,872,000. First Light Asset Management LLC boosted its stake in shares of NeoGenomics by 14.5% during the second quarter. First Light Asset Management LLC now owns 3,782,561 shares of the medical research company’s stock valued at $52,464,000 after purchasing an additional 480,396 shares during the period. Blue Trust Inc. grew its holdings in shares of NeoGenomics by 42.3% in the third quarter. Blue Trust Inc. now owns 3,318 shares of the medical research company’s stock worth $46,000 after purchasing an additional 987 shares during the last quarter. Finally, Sei Investments Co. increased its stake in shares of NeoGenomics by 152.6% in the second quarter. Sei Investments Co. now owns 263,761 shares of the medical research company’s stock worth $3,658,000 after buying an additional 159,350 shares during the period. 98.50% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have weighed in on NEO. Stephens reissued an “overweight” rating and set a $19.00 price target on shares of NeoGenomics in a research report on Tuesday, July 30th. Needham & Company LLC reissued a “buy” rating and issued a $19.00 target price on shares of NeoGenomics in a research note on Wednesday, November 6th. Finally, Benchmark restated a “buy” rating and set a $18.00 price target on shares of NeoGenomics in a report on Tuesday, September 24th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $20.25.

NeoGenomics Stock Down 3.9 %

Shares of NASDAQ:NEO opened at $15.79 on Friday. The firm has a market capitalization of $2.03 billion, a P/E ratio of -25.88 and a beta of 1.19. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.91 and a current ratio of 1.99. The stock has a 50 day moving average price of $14.70 and a 200-day moving average price of $14.80. NeoGenomics, Inc. has a 52-week low of $12.77 and a 52-week high of $21.22.

NeoGenomics (NASDAQ:NEO) last announced its earnings results on Tuesday, November 5th. The medical research company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.04. The firm had revenue of $167.80 million for the quarter, compared to analysts’ expectations of $167.00 million. NeoGenomics had a negative net margin of 12.07% and a negative return on equity of 2.11%. The company’s quarterly revenue was up 10.5% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.06) EPS. As a group, equities research analysts anticipate that NeoGenomics, Inc. will post -0.17 EPS for the current fiscal year.

NeoGenomics Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.